UTHR (United Therapeutics) Risk Assessment


UTHR United Therapeutics Corp UTHR
88 GF Score
Price $547.06
GF Value $387.04
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is United Therapeutics Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of United Therapeutics is: Low Risk: Strong fundamentals, worth long-term holding.

United Therapeutics  (NAS:UTHR) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

United Therapeutics Risk Assessment Related Terms

UTHR vs VTRS, NBIX, ZTS: Risk Assessment Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, United Therapeutics's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

United Therapeutics Risk Assessment vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, United Therapeutics's Risk Assessment distribution charts can be found below:

* The bar in red indicates where United Therapeutics's Risk Assessment falls into.


UTHR
88GF Score
United Therapeutics Corp UTHR
Risk Assessment is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is United Therapeutics (UTHR) Overvalued in 2026?

Based on GuruFocus' analysis, United Therapeutics stock appears to be overvalued. The current stock price of $547.06 is trading 41.3% above its estimated GF Value™ of $387.04. GuruFocus considers United Therapeutics to be Significantly Overvalued.

Key valuation signals for UTHR:

  • Risk Assessment:
  • GF Value™: $387.04 vs. price of $547.06 (41.3% above fair value)
  • GF Score™: 88/100 with 7 warning signs

No single metric tells the full story. See the UTHR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

United Therapeutics Business Description

Other Exchanges UTH:GermanyU2TH34:Brazil
Address 1000 Spring Street, Silver Spring, MD, USA, 20910
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
88GF Score

Get the complete analysis for UTHR

Risk Assessment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$547.06
Price
$387.04
GF Value